Achieve Life Sciences Inc. has released a corporate presentation highlighting Cytisinicline as a potential new treatment for nicotine dependence, marking the first advancement in nearly 20 years. The company targets a substantial market of up to 50 million Americans who use tobacco, aiming to address the significant public health issue of nicotine dependence. The presentation outlines the anticipated FDA approval timeline, with a smoking cessation NDA filed and a launch expected in the second half of 2026. Additionally, the company is preparing for Phase 3 trials for an e-cigarette cessation indication, which holds an FDA Breakthrough Therapy designation and Priority Review. Achieve Life Sciences plans a focused launch strategy utilizing innovative, data-driven solutions to promote adoption and future growth. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.